CHAM
TXMD icon

Clear Harbor Asset Management’s TherapeuticsMD TXMD Stock Holding History

Clear Harbor Asset Management’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-25,809
Closed -$59.1K – 395
2024
Q1 		$59.1K Buy
+25,809
New +$59.8K 0.01% 354

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Clear Harbor Asset Management's TXMD Position: Q2 2024 in Review

Clear Harbor Asset Management sold out of TherapeuticsMD (TXMD) in Q2 2024, closing a stake of 25,809 shares — an estimated $59.1K sold.

Clear Harbor Asset Management first reported a position in TXMD in Q1 2024 and held it in 1 quarter. The position peaked at $59.1K in Q1 2024. 38 funds tracked by Wall St. Rank hold TXMD as of Q2 2024.

  • Clear Harbor Asset Management reported no remaining TherapeuticsMD position as of Q2 2024 after selling out during the quarter.
  • Clear Harbor Asset Management sold 25,809 TherapeuticsMD shares in Q2 2024, an estimated $59.1K.
  • Clear Harbor Asset Management first reported a position in TherapeuticsMD in Q1 2024 and held it in 1 quarter.
  • Clear Harbor Asset Management's TherapeuticsMD position peaked at $59.1K in Q1 2024.
  • 38 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2024.

Based on Clear Harbor Asset Management's 13F filing for Q2 2024, filed 17 Jul 2024.